Literature DB >> 32598246

Human Vaccines & Immunotherapeutics: news.

.   

Abstract

Entities:  

Year:  2020        PMID： 32598246      PMCID： PMC7482739          DOI： 10.1080/21645515.2020.1778422

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  6 in total

1.  A bivalent, spherical virus-like particle vaccine enhances breadth of immune responses against pathogenic Ebola viruses in rhesus macaques.

Authors:  Karnail Singh; Bishal Marasini; Xuemin Chen; Lingmei Ding; Jaang-Jiun Wang; Peng Xiao; Francois Villinger; Paul Spearman
Journal:  J Virol       Date:  2020-02-19       Impact factor: 5.103

2.  Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.

Authors:  Matthew D Galsky; Amir Mortazavi; Matthew I Milowsky; Saby George; Sumati Gupta; Mark T Fleming; Long H Dang; Daniel M Geynisman; Radhika Walling; Robert S Alter; Mohamad Kassar; Jue Wang; Shilpa Gupta; Nancy Davis; Joel Picus; George Philips; David I Quinn; G Kenneth Haines; Noah M Hahn; Qianqian Zhao; Menggang Yu; Sumanta K Pal
Journal:  J Clin Oncol       Date:  2020-04-09       Impact factor: 44.544

3.  Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours.

Authors:  Aslan Mansurov; Jun Ishihara; Peyman Hosseinchi; Lambert Potin; Tiffany M Marchell; Ako Ishihara; John-Michael Williford; Aaron T Alpar; Michal M Raczy; Laura T Gray; Melody A Swartz; Jeffrey A Hubbell
Journal:  Nat Biomed Eng       Date:  2020-04-13       Impact factor: 25.671

4.  Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria.

Authors:  Michal Fried; Patrick E Duffy; Jonathan D Kurtis; Dipak K Raj; Alok Das Mohapatra; Anup Jnawali; Jenna Zuromski; Ambrish Jha; Gerald Cham-Kpu; Brett Sherman; Rachel M Rudlaff; Christina E Nixon; Nicholas Hilton; Andrew V Oleinikov; Olga Chesnokov; Jordan Merritt; Sunthorn Pond-Tor; Lauren Burns; Grant Jolly; Choukri Ben Mamoun; Edward Kabyemela; Atis Muehlenbachs; Lynn Lambert; Sachy Orr-Gonzalez; Nina F Gnädig; David A Fidock; Sangshin Park; Jeffrey D Dvorin; Norbert Pardi; Drew Weissman; Barbara L Mui; Ying K Tam; Jennifer F Friedman
Journal:  Nature       Date:  2020-04-22       Impact factor: 69.504

5.  Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.

Authors:  Till Koch; Christine Dahlke; Anahita Fathi; Alexandra Kupke; Verena Krähling; Nisreen M A Okba; Sandro Halwe; Cornelius Rohde; Markus Eickmann; Asisa Volz; Thomas Hesterkamp; Alen Jambrecina; Saskia Borregaard; My L Ly; Madeleine E Zinser; Etienne Bartels; Joseph S H Poetsch; Reza Neumann; Robert Fux; Stefan Schmiedel; Ansgar W Lohse; Bart L Haagmans; Gerd Sutter; Stephan Becker; Marylyn M Addo
Journal:  Lancet Infect Dis       Date:  2020-04-21       Impact factor: 25.071

6.  Development of an inactivated vaccine candidate for SARS-CoV-2.

Authors:  Qiang Gao; Linlin Bao; Haiyan Mao; Lin Wang; Kangwei Xu; Minnan Yang; Yajing Li; Ling Zhu; Nan Wang; Zhe Lv; Hong Gao; Xiaoqin Ge; Biao Kan; Yaling Hu; Jiangning Liu; Fang Cai; Deyu Jiang; Yanhui Yin; Chengfeng Qin; Jing Li; Xuejie Gong; Xiuyu Lou; Wen Shi; Dongdong Wu; Hengming Zhang; Lang Zhu; Wei Deng; Yurong Li; Jinxing Lu; Changgui Li; Xiangxi Wang; Weidong Yin; Yanjun Zhang; Chuan Qin
Journal:  Science       Date:  2020-05-06       Impact factor: 47.728
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.